Paul Forsyth

Dr. Paul Forsyth

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2021 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
JBJanine Beezer
Janine Beezer
MHManal Al Hatrushi
Manal Al Hatrushi
AHAndy Husband
Andy Husband
Amanj KurdiAmanj Kurdi
Amanj Kurdi
PFPaul Forsyth
Paul Forsyth

20 July 2021 in Circulation
Verified
Journal Article
Open access
PDF file
KDKieran F. Docherty
Kieran F. Docherty
RCRoss T. Campbell
Ross T. Campbell
KBKatriona J.M. Brooksbank
Katriona J.M. Brooksbank
JDJohn G. Dreisbach
John G. Dreisbach
PFPaul Forsyth
Paul Forsyth
JMJohn J.V. McMurray
John J.V. McMurray
Background: Patients with left ventricular (LV) systolic dysfunction after myocardial infarction are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin angiotensin system inhibition may result in greater attenuation of adverse LV remodeling as a result of increased levels of substrates for neprilysin with vasodilatory, antihypertrophic, antifibrotic, and sympatholytic effects. Methods: We performed a prospective, multicenter, randomized, double-blind, active-comparator trial comparing sacubitril/valsartan 97/103 mg twice daily with valsartan 160 mg twice daily in patients ≥3 months after myocardial infarction with a LV ejection fraction ≤40% who were taking a renin angiotensin system inhibitor (equivalent dose of ramipril ≥2.5 mg twice daily) and a β-blocker unless contraindicated or intolerant. Patients in New York Heart Association class ≥II or with signs and symptoms of heart failure were excluded. The primary outcome was change from baseline to 52 weeks in LV end-systolic volume index measured using cardiac magnetic resonance imaging. Secondary outcomes included other magnetic resonance imaging measurements of LV remodeling, change in NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity cardiac troponin I, and a patient global assessment of change questionnaire. Results: From July 2018 to June 2019, we randomized 93 patients with the following characteristics: mean age, 60.7±10.4 years; median time from myocardial infarction, 3.6 years (interquartile range, 1.2–7.2); mean LV ejection fraction, 36.8%±7.1%; and median NT-proBNP, 230 pg/mL (interquartile range, 124–404). Sacubitril/valsartan, compared with valsartan, did not significantly reduce LV end-systolic volume index; adjusted between-group difference, –1.9 mL/m 2 (95% CI, –4.8 to 1.0); P =0.19. There were no significant between-group differences in NT-proBNP, high-sensitivity cardiac troponin I, LV end-diastolic volume index, left atrial volume index, LV ejection fraction, LV mass index, or patient global assessment of change. Conclusions: In patients with asymptomatic LV systolic dysfunction late after myocardial infarction, treatment with sacubitril/valsartan did not have a significant reverse remodeling effect compared with valsartan. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03552575.

7 June 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JFJocelyn M Friday
Jocelyn M Friday
JCJohn George Franklin Cleland
John George Franklin Cleland
PPPierpaolo Pellicori
Pierpaolo Pellicori
MWMaria K Wolters
Maria K Wolters
JMJohn J V McMurray
John J V McMurray
JLJim Lewsey
Jim Lewsey
Background and Aims: Many patients are prescribed loop diuretics without a diagnostic record of heart failure. Little is known about their characteristics and prognosis. Methods: Glasgow regional health records (2009–16) were obtained for adults with cardiovascular disease or taking loop diuretics. Outcomes were investigated using Cox models with hazard ratios adjusted for age, sex, socioeconomic deprivation, and comorbid disease (adjHR). Results: Of 198 898 patients (median age 65 years; 55% women), 161 935 (81%) neither took loop diuretics nor had a diagnostic record of heart failure (reference group), 23 963 (12%) were taking loop diuretics but had no heart failure recorded, 7844 (4%) had heart failure recorded and took loop diuretics, and 5156 (3%) had heart failure recorded but were not receiving loop diuretics. Compared to the reference group, five-year mortality was only slightly higher for heart failure in the absence of loop diuretics [22%; adjHR 1.2 (95% CI 1.1–1.3)], substantially higher for those taking loop diuretics with no record of heart failure [40%; adjHR 1.8 (95% CI 1.7–1.8)], and highest for heart failure treated with loop diuretics [52%; adjHR 2.2 (95% CI 2.0–2.2)]. Conclusions: For patients with cardiovascular disease, many are prescribed loop diuretics without a recorded diagnosis of heart failure. Mortality is more strongly associated with loop diuretic use than with a record of heart failure. The diagnosis of heart failure may be often missed, or loop diuretic use is associated with other conditions with a prognosis similar to heart failure, or inappropriate loop diuretic use increases mortality; all might be true.

24 January 2019 in International Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
PFPaul Forsyth
Paul Forsyth
JRJanice Richardson
Janice Richardson
RLRichard Lowrie
Richard Lowrie

2 September 2022 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
PFPaul Forsyth
Paul Forsyth
ARAndrew Radley
Andrew Radley
GRGordon Rushworth
Gordon Rushworth
FMFiona Marra
Fiona Marra
SRSusan Roberts
Susan Roberts
BMBarry Maguire
Barry Maguire

15 May 2021 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
PFPaul Forsyth
Paul Forsyth
GRGordon F. Rushworth
Gordon F. Rushworth